FOLLOWUS
Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis
Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis
- Chinese Journal of Integrative Medicine 2022年28卷第4期 页码：374-383
- Affiliations：
1.National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing (100091), China
2.Tianjin Medical University Cancer Institute and Hospital, Tianjin (300060), China
3.First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin (300112), China
- Author bio：
Prof. LIU Long-tao, E-mail: liulongtao1976@126.com
- Funds：the National Natural Science Foundation of China(81973689;82074254);the Beijing Natural Science Foundation of China(7202176)
DOI：10.1007/s11655-022-2884-5
中图分类号：纸质出版日期：2022-04，
录用日期：2021-09-13
Scan for full text
Xiao-nan ZHANG, Yan-yang LI, Yuan-hui ZHANG, 等. Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis[J]. Chinese Journal of Integrative Medicine, 2022,28(4):374-383.
Xiao-nan ZHANG, Yan-yang LI, Yuan-hui ZHANG, et al. Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis[J]. Chinese Journal of Integrative Medicine, 2022,28(4):374-383.
Xiao-nan ZHANG, Yan-yang LI, Yuan-hui ZHANG, 等. Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis[J]. Chinese Journal of Integrative Medicine, 2022,28(4):374-383. DOI： 10.1007/s11655-022-2884-5.
Xiao-nan ZHANG, Yan-yang LI, Yuan-hui ZHANG, et al. Shengmai San for Treatment of Cardiotoxicity from Anthracyclines: A Systematic Review and Meta-Analysis[J]. Chinese Journal of Integrative Medicine, 2022,28(4):374-383. DOI： 10.1007/s11655-022-2884-5.
摘要
目的:
2
系统评价生脉散治疗蒽环类药物心脏毒性患者的疗效.
方法:
2
通过检索自建库至2020年12月中国知网 (CNKI) 、万方、中国生物医学文献数据库 (CBM) 、PubMed、Cochrane Library和 Embase 数据库的随机对照试验 (RCTs)
采用Cochrane 手册评估纳入研究的偏倚风险
RevMan 5.3软件进行Meta分析.
结果:
2
共纳入19项RCTs
2331 名参与者
结果显示
在改善心律失常方面(13 RCTs
n=1877
RR=0.37
95% CI 0.25 to 0.52
P
<
0.00001)
治疗组优于对照组; 在减小左心室舒张末期内径 (LVEDD
2 RCTs
n
=128
MD=–0.79
95% CI –0.93 to –0.65
P
<
0.00001) 和左心室收缩末期内径 (LVESD
2 RCTs
n
=128
MD=–0.58
95% CI –0.82 to –0.35
P
<
0.00001)
治疗组同样优于对照组; 在降低心肌酶方面如肌酸激酶 (CK) [(3 RCTs
n
=256
SMD=–0.80
95% CI –1.16 to –0.44
P
<
0.0001)
(2 RCTs
n
=126
SMD=– 0.62
95% CI –0.98 to –0.26
P
=0.0007)]
治疗组优于对照组.
结论:
2
生脉散对蒽环类药物心脏毒性的治疗具有积极作用
但未来仍需开展高质量的RCTs来验证其疗效.
Abstract
Objective:
2
To systematically evaluate the efficacy of Shengmai San in patients with cardiotoxicity of anthracyclines.
Methods:
2
Randomized controlled trials (RCTs) were identified by searching China National Knowledge Infrastructure (CNKI)
Wanfang Database
Chinese Biomedical Literature Database (CBM)
PubMed
Cochrane Library
and Embase Databases from the inceptions until December 2020. The Cochrane Handbook was used to evaluate the risk of bias in the included studies. Data analysis was conducted using RevMan 5.3 software.
Results:
2
Totally 19 RCTs with 2
331 participants were included in this review. Results showed that in improving arrhythmia (13 RCTs
n
=1
877
RR=0.37
95% CI 0.25 to 0.52
P
<
0.00001)
the treatment group was superior to the control group. In terms of reducing left ventricular end-diastolic diameter (LVEDD
2 RCTs
n
=128
MD=–0.79
95% CI –0.93 to –0.65
P
<
0.00001) and left ventricular end systolic diameter (LVESD
2 RCTs
n
=128
MD=–0.58
95% CI –0.82 to –0.35
P
<
0.00001)
the treatment group was also better than the control group. In reducing myocardial enzymes such as creatine kinase (CK) [(3 RCTs
n
=256
SMD=–0.80
95% CI –1.16 to –0.44
P
<
0.0001)
(2 RCTs
n
=126
SMD=–0.62
95% CI –0.98 to –0.26
P
=0.0007)]
the treatment group was superior to the control group.
Conclusion:
2
Shengmai San has a positive effect on the treatment of cardiotoxicity from anthracyclines. However
in the future
it is still necessary to conduct high-quality RCTs to verify its efficacy.
关键词
Keywords
Shengmai Sananthracyclinescardiotoxicitysystematic reviewmeta-analysis
references
Vejpongsa P, Yeh ET. Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities. J Am Coll Cardiol 2014;64:938-945.
Ma J, Qin SK, Shen ZX. Guidelines for the prevention and treatment of cardiotoxicity of anthracyclines (2013 edition).J Clin Oncol (Chin) 2013;18:925-934.
Patane S. Cardiotoxicity: anthracyclines and long term cancer survivors. Int J Cardiol 2014;176:1326-1328.
Chung WB, Youn HJ. Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. Korean J Intern Med 2016;31:625-633.
Cruz M, Duarte-Rodrigues J, Campelo M. Cardiotoxicity in anthracycline therapy: Prevention strategies. Rev Port Cardiol 2016;35:359-371.
Seif A E, Walker DM, Li Y, et al. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer 2015;62:704-709.
Li WT, Yu BY, Wu MH. Zhou Zhongying's experience in treating postoperative lung cancer patients from the view of qi and yin deficiency. J Tradit Chin Med (Chin) 2016;57:643-645.
Cao P, Zheng GY, Ruan Y, Yao M, Yue XQ. Professor Ling Chang-quan's experience in treating malignant tumor based"cancer toxicity" theory. Chin J Integr Tradit Chin West Med(Chin) 2020;40:1-4.
Li YY, Sun HY, Jiang ZS, et al. Research on the prevention and treatment of cardiac toxicity of antitumor drugs in traditional Chinese medicine. J Basic Chin Med (Chin)2018;24:1602-1606.
Hao W, Liu S. Research progress on prevention of anthracycline-induced cardiotoxicty by Chinese medicine.Shanghai J Tradit Chin Med (Chin) 2016;50:99-102.
Chen YF, Yu RY, Xiong YK, et al. Application and mechanism of traditional Chinese medicine in preventing and treatment of adriamycin-induced cardiotoxicity. Chin J Exp Tradit Med Form (Chin) 2018;24:207-217
Zhang JH, Wu CJ, Cai G, et al. Systematic evaluation of Shenmai Injection for prevention and treatment of cardiotoxicity induced by chemotherapy of malignant tumor.Chin J Inf Tradit Chin Med (Chin) 2018;25:96-100.
Wang Y. Study on the protective effect of Shengmai Yin combined with benazepril on cardiac function in patients with chronic heart failure induced by tumor drugs. J Cardiovasc Cerebrovasc Dis Integr Tradit Chin West Med(Chin) 2018;16:1156-1160.
Huang YF. Evaluation of the effect of combined treatment of dexrazoxane and Shenmai Injection on reducing cardiotoxicity in chemotherapy of acute leukemia. Cardiovasc Dis Electronic J Integr Traditi Chin West Med (Chin) 2018;6:156158.
Fang GY, Zhang QM, Wei AQ, et al. Shenmai combined with dexrazoxane in the prevention and treatment of cardiotoxicity in 31 patients with breast cancer caused by anthracycline. Chin J Critical Care Med (electronic edition, Chin) 2017;10:406-407.
LV ZH, Jiang SQ. Influence of combined treatment of dexrazoxane and Shenmai Injection on reducing cardiotoxicity in the acute leukemia chemotherapy. J Tropical Med (Chin) 2017;17:633-636.
Wang YL, Li JL, Yan ZH, et al. Evaluation of the efficacy of Shenmai Injection in improving the cardiac side effects of drugs. Chin Pract Med (Chin) 2017;12:123-125.
Yu W, Guo ZQ, Xie RX, et al. Clinical observation of the reduction of anthracycline-induced cardiotoxicity in patients with breast cancer by dexrazoxane combined with Shenmai Injection. Chin Pharm (Chin) 2015;26:4562-4564.
Liu Q, Zhang XF, Cheng XF, et al. Clinical observation of cardiac toxicity induced by FAC regimen in female breast cancer treated by Shenmai Injection. Acta Chin Med (Chin)2014;29:1090-1091,1094.
Li QY, Zhu LM, Li YB, et al. Protective effect of Shenmai Injection for cardiac muscle of breast cancer patients during pirarubicin chemotherapy. Youjiang Med J (Chin)2014;42:669-671.
Ma FC. Effect of Shenmai Injection on myocardial enzyme level in patients with malignant tumor receiving epirubicin chemotherapy. J Basic Clin Oncol (Chin) 2014;27:66-67.
Su YW. Clinical observation of Shenmai Injection in the prevention and treatment of cardiotoxicity of epirubicin.World Late Med (electronic version, Chin) 2013;5:189-190.
Ge Y, Hu XL, Hao DS, et al. Cardioprotective effect of Shenmai Injection on chemotherapy in patients with acute leukemia. World Health Digest (Chin) 2013;33:70.
Wang CY, Song CY, Shen FM. Study on the protective effect of Shenmai Injection on cardiotoxicity of doxorubicin.Clin Focus (Chin) 2012;27:1169-1170.
Zhang J. Myocardial protective effect of Shengmai Injection on doxorubicin chemotherapy in patients with malignant tumor. Guangming J Chin Med (Chin) 2011;26:530.
Yang XL, Zhang H, Hou YM. Myocardium protective effects of Shenmai Injection to Xinjiang women with breast cancer subject to 5-fluorouracil chemotherapy. J Clin Cardiol (Chin)2011;27:138-141.
Chen HL. Observation of Shenmai Injection in preventing cardiotoxicity of anthracycline chemotherapeutic drugs.Zhejiang J Tradit Chin Med (Chin) 2009;12:928
Li Q, Zhang WJ, Ma QZ, et al. Electrocardiographic observation of Shenmai Injection in the treatment of cardiotoxicity induced by doxorubicin. Mili Med J South Chin (Chin) 2008;10:43-45.
Yang XL. Clinical observation on the prevention of doxorubicin-associated cardiotoxicity by Shengmai Injection. Guide Chin Med (Chin) 2008;6:203-205.
Wang RQ, Xie Y, Zhao SZ. Clinical observation of Shengmai Injection in the prevention and treatment of cardiotoxicity induced by doxorubicin. Chin J Int Med Cardio-Cerebrovasc Dis (Chin) 2006;4:1092-1093.
Xiong P, Lian J, Yu XQ. An electrocardiogram analysis in 83 galactophore cancer patients in ADM chemotherapy.Proc Clin Med (Chin) 2006;15:263-264.
Sala V, Sala AD, Hirsch E, et al. Signaling pathways underlying anthracycline cardiotoxicity. Antioxid Redox Signal 2020;32:1098-1114.
Rocca C, Pasqua T, Cerra MC, et al. Cardiac damage in anthracyclines therapy: Focus on oxidative stress and inflammation. Antioxid Redox Signal 2020;32:1081-1097.
Cao ZH, Pan JH, Li N, et al. Modern pharmacological effect and mechanism of Shengmai San. Chin J Exp Tradit Med Form (Chin) 2019;25:212-218.
Zhou YL, You K. Two cases report of old people chronic heart failure treated by Shengmai Powder. J Pract Tradit Chin Intern Med (Chin) 2016;30:77-79.
Geng Y, Xu HY, Ma YX, et al. Composition principles of formula containing Shengmai San in dictionary of Chinese medicine prescription. Chin J Exp Tradit Med Form (Chin)2017;23:200-205.
Geng Y, Ma YX, Xu HY, et al. Drug Standards of the Ministry of Health of the People's Republic of China–Prescriptions of Chinese Medicines: An analysis of the prescription rules of Chinese patent medicines containing Shengmai San.Liaoning J Tradit Chin Med (Chin) 2017;44:1018-1021.
Wang HE, Bai WY, Liu Z, et al. Research progress of Shengmai prescription. Chin Tradit Patent Med (Chin) 2019;41:151-159.
Liu LK, Song W, Hao SL, et al. Reversal effect of Shengmai Injection containing serum on multidrug resistant human gastric cancer cell and its possible mechanism. China J Tradit Chin Med Pharm (Chin) 2018;33:4204-4208.
0
浏览量
6
Downloads
0
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
